Author

Zongjiu Jiao

Observed name: Jiao, Zongjiu

Observed institution: Xingtai People's Hospital

ORCID: 0009-0008-4268-964X

Observed ORCID: 0009-0008-4268-964X

OpenAlex ID: A5018197341

Venetoclax combined with daunorubicin and cytarabine (2 + 6) as induction treatment in adults with newly diagnosed acute myeloid leukemia: a phase 2, multicenter, single-arm trial

2023 · Xiaohui Suo, Fang Zheng, et al. · Experimental Hematology and Oncology · 19

PDF

Mast Cells as Targets of Pimecrolimus

2011 · Zhongcai Ma, Zongjiu Jiao · Current Pharmaceutical Design · 13

Zanubrutinib, Lenalidomide, Rituximab, Temozolomide and Methotrexate (RLZT±MTX) As First-Line Treatment for Newly Diagnosed PCNSL: A Prospective, Open-Lable, Multicenter Clinical Trial

2022 · Jia Song, Hui Liu, et al. · Blood · 7

MiR-22-3p regulates the SIRT1/P53 signaling pathway, thereby influencing ferroptosis in diffuse large B-cell lymphoma cells

2025 · Xin Lu, Liyun Zhao, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 4

Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemia

2024 · Xiaohui Suo, Xiaojun Ma, et al. · Blood Cancer Journal · 4

Efficacy and safety of OB756 (a novel selective JAK2 inhibitor) for essential thrombocythemia in patients intolerant of or resistant to hydroxyurea or intolerant of interferon: A phase 2, open‐label, multicenter study

2025 · Jian Huang, Rumeng Li, et al. · Cancer · 3

Detection of Osteocalcin in Serum Based on Electrochemical Sensing Technology

2022 · Lanfang Lv, Yehua Zhang, et al. · International Journal of Electrochemical Science · 3

miR-506 in patients with chronic myeloid leukemia and its effect on apoptosis of K562 cells.

2021 · Nafei Chen, Zhen Meng, et al. · American Journal of Translational Research · 3

Zanubrutinib, lenalidomide, rituximab, temozolomide ± methotrexate as first‐line treatment for primary central nervous system lymphoma: A prospective, open‐label, multicentre clinical trial

2026 · Jia Song, Huijuan Jiang, et al. · British Journal of Haematology · 2

PDF

A Novel JAK2 Inhibitor OB756 in Treatment of Janus Kinase Inhibitor-Naive Patients with Myelofibrosis: A Phase 1/2, Open-Label, Multicenter Study

2024 · Yile Zhou, Jian Huang, et al. · Blood · 2

PDF

miR-497-5p induces apoptosis in K562 cells by downregulating ROCK1.

2021 · Nafei Chen, Zhen Meng, et al. · American Journal of Translational Research · 2

Zanubrutinib, Lenalidomide, Rituximab, Temozolomide and Methotrexate (RLZT ± MTX) As First-Line Treatment for Newly Diagnosed PCNSL: A Prospective, Open-Label, Multicenter Clinical Trial

2024 · Rong Fu, Jia Song, et al. · Blood · 1

PDF

Venetoclax combined with daunorubicin and cytarabine (2 + 6) in acute myeloid leukemia: Updated results of a phase II trial

2024 · Xiaohui Suo, Zheng Fang, et al. · Hematological Oncology · 1

PDF

Efficacy and safety of OB756 (a Novel Selective JAK2 Inhibitor) for essential thrombocythemia in patients intolerant or resistant to hydroxyurea or interferon: A phase II, open-label, multicenter study

2025 · Jian Huang, Rumeng Li, et al. · Blood

PDF

Efficacy and Safety of Beceltinib Capsules in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia: A Multicenter, Randomized, Open-Label, Phase 1/2 Study

2024 · Hu Zhou, Xuewen Song, et al. · Blood

PDF

Venetoclax Combined with Daunorubicin and Cytarabine (2 + 6) in Acute Myeloid Leukemia: Updated Results of a Phase II Trial

2023 · Xiaohui Suo, Dongmei Wang, et al. · Blood

Works count: 21

Citation count: 64

H-index: 4

I10-index: 2